Komori
Other Disclosures2395SHIN NIPPON BIOMEDICAL LABORATORIES,LTD.Information and Communications, Services and Others

Continued inclusion in the constituents of the ESG indices “FTSE JPX Blossom Japan Index” and “FTSE JPX Blossom Japan Sector Relative Index”

Shin Nippon Biomedical Laboratories, Ltd. continued to be selected as a constituent of the ESG indices “FTSE JPX Blossom Japan Index” and “FTSE JPX Blossom Japan Sector Relative Index.” This marks the second consecutive year of selection for the former and the fifth consecutive year for the latter.

Worth reading
41Recurring
0–100. This measures how worthwhile something is to read, not how good or bad the company is.
Direction
Improvement
Direction inferred from the company’s description.
Scale
—
Displayed only when the document provides numerical figures.
Wording
Definitive
How definitive the wording is.

Announced details

FTSE JPX Blossom Japan IndexFTSE JPX Blossom Japan Sector Relative Index
Applicable field (uses covered by this announcement)

Creation and evaluation of ESG and sustainable investment funds and financial products

Launch dateContinued selection as of 6 July 2026 (track record)
What the company reported numerically
Quantitative Effects

FTSE JPX Blossom Japan Index: selected for 2 consecutive years; FTSE JPX Blossom Japan Sector Relative Index: selected for 5 consecutive years. Constituent of 3 ESG indices adopted by GPIF (as of 6 July 2026)

Relationship between the counterparty and the company
SHIN NIPPON BIOMEDICAL LABORATORIES,LTD.2395
Relationship with the Company

Shin Nippon Biomedical Laboratories, Ltd. has been selected as a constituent of ESG indices created by FTSE Russell. Both indices have been adopted as benchmarks for ESG passive investments selected by GPIF. Capital and personnel relationships are Not disclosed.

CounterpartyFTSE Russell and the Government Pension Investment Fund (GPIF)

FTSE Russell: Global index provider. GPIF: Government Pension Investment Fund. Other information, including location, representative, capital and year of establishment, is Not disclosed.

Location (as indicated in this announcement)

Kagoshima, Kagoshima Prefecture (head office of Shin Nippon Biomedical Laboratories, Ltd.)

In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.

Source (materials cited by the company)

FTSE Russell、GPIF

Announced details
ItemDetails
Names of Products / Services CoveredFTSE JPX Blossom Japan Index, FTSE JPX Blossom Japan Sector Relative Index
CounterpartyFTSE Russell and the Government Pension Investment Fund (GPIF)
Counterparty overviewFTSE Russell: Global index provider. GPIF: Government Pension Investment Fund. Other information, including location, representative, capital and year of establishment, is Not disclosed.
Relationship with the CompanyShin Nippon Biomedical Laboratories, Ltd. has been selected as a constituent of ESG indices created by FTSE Russell. Both indices have been adopted as benchmarks for ESG passive investments selected by GPIF. Capital and personnel relationships are Not disclosed.
Launch dateContinued selection as of 6 July 2026 (track record)
Applicable areaCreation and evaluation of ESG and sustainable investment funds and financial products
LocationKagoshima, Kagoshima Prefecture (head office of Shin Nippon Biomedical Laboratories, Ltd.)
Quantitative EffectsFTSE JPX Blossom Japan Index: selected for 2 consecutive years; FTSE JPX Blossom Japan Sector Relative Index: selected for 5 consecutive years. Constituent of 3 ESG indices adopted by GPIF (as of 6 July 2026)
SourceFTSE Russell、GPIF
Items this document does not state (9)
Contract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocation scaleUsage historyImpact on Business Performance

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

The indices were created by FTSE Russell to measure the performance of companies demonstrating outstanding approaches to environmental, social and governance (ESG) issues. Constituent companies are considered to meet various ESG-related criteria.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Continued inclusion in the constituents of the ESG indices “FTSE JPX Blossom Japan Index” and “FTSE JPX Blossom Japan Sector Relative Index” | SHIN NIPPON BIOMEDICAL LABORATORIES,LTD. (2395) timely disclosure | Komori